US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OS Therapies

1.82

-0.0200-1.09%

Pre-market: 1.930.0800+4.32%04:03 EDT

Volume:186.59K

Turnover:335.11K

Market Cap:51.14M

PE:-2.22

High:1.87

Open:1.79

Low:1.73

Close:1.84

Loading ...

Overview Company News Filings

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESS Newswire

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27

OS Therapies Forms Drug Conjugates Unit, Reviews Options for Tunable ADC, Drug Conjugates Platforms

MT Newswires Live

OS Therapies Is Maintained at Buy by D. Boral Capital

Os Therapies Forms Subsidiary Os Drug Conjugates and Initiates Review of Strategic Options for Its Tunable ADC & Drug Conjugates Platforms

THOMSON REUTERS

Os Therapies Inc - in Discussions to Form Joint Ventures With ADC Companies

THOMSON REUTERS

OS Therapies receives patent notice of allowance for OST-HER2

Sector Update: Health Care Stocks Decline Late Afternoon

MT Newswires Live

Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer

BUZZ-OS Therapies rises after starting commercial production of cancer therapy

OS Therapies Says It Signed Manufacturing Deal for Lead Candidate OST-HER2

MT Newswires Live

BRIEF-OS Therapies Initiates Commercial-Ready Manufacturing Of OST-HER2 To Support Anticipated Biologics Licensing Authorization (BLA) Filing

Os Therapies Initiates Commercial-Ready Manufacturing of Ost-Her2 to Support Anticipated Biologics Licensing Authorization (Bla) Filing

THOMSON REUTERS

Os Therapies: Evaluating Strategic Options for Tunable Antibody Drug Conjugate Platform

THOMSON REUTERS

Os Therapies Provides Corporate Update

THOMSON REUTERS

OS Therapies files to sell 10.83M shares of common stock for holders

OS Therapies to Acquire Certain Ayala Pharmaceuticals Assets

MT Newswires Live

OS Therapies to acquire listeria programs from Ayala Pharmaceuticals

Amex Halt News Pending Lst 2.600000

THOMSON REUTERS

Os Therapies Inc - to Request Bla for Ost-Her2 in Q2 2025

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/OSTX/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OSTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OSTX\",,,,,undefined,":{"symbol":"OSTX","market":"US","secType":"STK","nameCN":"OS Therapies","latestPrice":1.82,"timestamp":1749844800000,"preClose":1.84,"halted":0,"volume":186589,"hourTrading":{"tag":"盘前","latestPrice":1.93,"preClose":1.85,"latestTime":"04:03 EDT","volume":433,"amount":833.6200002,"timestamp":1750061016628},"delay":0,"floatShares":18778400,"shares":28097697,"eps":-0.819717,"marketStatus":"Pre-Mkt","change":-0.02,"latestTime":"06-16 05:23:14 EDT","open":1.79,"high":1.87,"low":1.73,"amount":335107.0521604,"amplitude":0.076087,"askPrice":2.07,"askSize":100,"bidPrice":1.66,"bidSize":109,"shortable":3,"etf":0,"ttmEps":-0.819717,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1750080600000},"marketStatusCode":1,"adr":0,"listingDate":1719460800000,"exchange":"AMEX","adjPreClose":1.85,"preHourTrading":{"tag":"盘前","latestPrice":1.93,"preClose":1.85,"latestTime":"04:03 EDT","volume":433,"amount":833.6200002,"timestamp":1750061016628},"postHourTrading":{"tag":"盘后","latestPrice":1.78,"preClose":1.82,"latestTime":"19:38 EDT","volume":1395,"amount":2554.6518,"timestamp":1749857925129},"volumeRatio":0.31820578656515647},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OSTX\",,,,,undefined,":{"symbol":"OSTX","floatShares":18778400,"roa":"-263.81%","roe":"--","lyrEps":-0.879526,"volumeRatio":0.31820578656515647,"shares":28097697,"dividePrice":0,"high":1.87,"amplitude":0.076087,"preClose":1.84,"low":1.73,"week52Low":1.12,"pbRate":"-12.21","week52High":7,"institutionHeld":0,"latestPrice":1.82,"committee":0.043062,"eps":-0.819717,"divideRate":0,"volume":186589,"delay":0,"ttmEps":-0.819717,"open":1.79,"prevYearClose":4.28,"prevWeekClose":1.82,"prevMonthClose":1.53,"prevQuarterClose":1.54,"fiveDayClose":1.67,"twentyDayClose":1.66,"sixtyDayClose":1.52},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OSTX\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514189327","title":"Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV","url":"https://stock-news.laohu8.com/highlight/detail?id=2514189327","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514189327?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:00","pubTimestamp":1740751200,"startTime":"0","endTime":"0","summary":"ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc.  and OS Therapies Inc.  on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV this Saturday, March 1, at 7 p.m. Eastern Time . Bloomberg TV is available in an estimated 73 million homes across the U.S.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/calidi-biotherapeutics-os-therapies-interviews-140000113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4561","BK4581","03160","BK4604","ADC","OSTX","BK4097","CLDI","BK4187","BK4099","ET","BK4231","BK4555","TM","TV","AIRI","BK4590","BK4100","OS","BK4588","BK4585","BK4080","BK4144"],"gpt_icon":0},{"id":"2514186726","title":"Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27","url":"https://stock-news.laohu8.com/highlight/detail?id=2514186726","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514186726?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:01","pubTimestamp":1740603660,"startTime":"0","endTime":"0","summary":"NEW YORK, February 26, 2025----OS Therapies  , a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, is pleased to invite investors to a webinar on February 27, 2025, at 4:15 p.m. ET.The exclusive event, hosted by RedChip Companies, will feature OS Therapies’ Chairman and CEO, Paul Romness, and Chief Business Officer, Gerald Commissiong, who will provide an in-depth update on the Company’s rapidly advancing pipeline. OS Therapies is pioneering groundbreaking immunotherapies and antibody-drug conjugates  to address critical unmet needs in pediatric and young adult oncology, as well as a broad range of solid tumors. The Company’s lead candidate, OST-HER2, has demonstrated statistically significant improvements in 12-month event-free survival for recurrent, fully resected metastatic osteosarcoma, positioning it as a potential first-in-class treatment with accelerated FDA approval pathways. Additionally, OS Therapies’ proprietary Tunable Antibody Drug Conjug","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/join-os-therapies-exclusive-live-210100765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","OS","BK4097","BK4231","ADC","BK4080","OSTX"],"gpt_icon":0},{"id":"2513072902","title":"OS Therapies Forms Drug Conjugates Unit, Reviews Options for Tunable ADC, Drug Conjugates Platforms","url":"https://stock-news.laohu8.com/highlight/detail?id=2513072902","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513072902?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:43","pubTimestamp":1740404601,"startTime":"0","endTime":"0","summary":"OS Therapies  said Monday it has formed OS Drug Conjugates unit and initiated a review of strategic options for its tunable antibody-drug conjugates and other tunable drug conjugates platforms.The biotechnology company said it has started talks with antibody-drug conjugates therapeutics companies in the US, China, and other jurisdictions for potential joint ventures that will be spun off into standalone public companies.Shares of the company rose more than 8% in recent Monday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADC","OSTX","BK4139","BK4080","BK4231"],"gpt_icon":0},{"id":"2513872504","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2513872504","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513872504?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:00","pubTimestamp":1740402000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2025 08:00 ET (13:00 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2513723879","title":"Os Therapies Forms Subsidiary Os Drug Conjugates and Initiates Review of Strategic Options for Its Tunable ADC & Drug Conjugates Platforms","url":"https://stock-news.laohu8.com/highlight/detail?id=2513723879","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513723879?lang=en_us&edition=fundamental","pubTime":"2025-02-24 20:25","pubTimestamp":1740399900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUAB5BPPP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2513233127","title":"Os Therapies Inc - in Discussions to Form Joint Ventures With ADC Companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2513233127","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513233127?lang=en_us&edition=fundamental","pubTime":"2025-02-24 20:25","pubTimestamp":1740399900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUAB5BPPP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2512412906","title":"OS Therapies receives patent notice of allowance for OST-HER2","url":"https://stock-news.laohu8.com/highlight/detail?id=2512412906","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512412906?lang=en_us&edition=fundamental","pubTime":"2025-02-20 18:20","pubTimestamp":1740046834,"startTime":"0","endTime":"0","summary":"OS Therapies (OSTX) announced that it received a notice of allowance from the United States Patent & Trademark Office that a patent will be issued ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/os-therapies-receives-patent-notice-of-allowance-for-ost-her2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/os-therapies-receives-patent-notice-of-allowance-for-ost-her2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OSTX","BK4148","OST","BK4139"],"gpt_icon":0},{"id":"2511612270","title":"Sector Update: Health Care Stocks Decline Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2511612270","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511612270?lang=en_us&edition=fundamental","pubTime":"2025-02-15 04:57","pubTimestamp":1739566675,"startTime":"0","endTime":"0","summary":"Health care stocks were lower late Friday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund  each shedding about 0.9%.The iShares Biotechnology ETF  eased 0.2%.In corporate news, enGene  shares fell past 7% after UBS downgraded the stock to neutral from buy and cut its price target to $7 from $34.Moderna  reported a Q4 loss of $2.91 per share, worse than the $2.83 loss expected in a FactSet poll. Revenue was $966 million, better than the consensus estimate of $942.8 million. Its shares gained about 4%.OS Therapies  shares jumped 12%. The firm said it signed agreements for the commercial-ready manufacturing of OST-HER2 to support anticipated Biologics Licensing Authorization filing.West Pharmaceutical Services  shares popped past 7%.  Deutsche upgraded the stock to buy from hold while lowering its price target to $250 from $275.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4551","IBB","BK4548","MRNA","BK4588","BK4121","WST","BK4534","BK4581","BK4567","NPCE","XLV","IE00BYQQ9H92.USD","BK4568","IE00BFXG0V08.USD","BK4585","BK4501","BK4533","OSTX","IE00B64QTZ34.USD","BK4532","BK4504","BK4539","BK4082","ENGN","BK4139"],"gpt_icon":1},{"id":"2511645023","title":"Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2511645023","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511645023?lang=en_us&edition=fundamental","pubTime":"2025-02-15 02:51","pubTimestamp":1739559089,"startTime":"0","endTime":"0","summary":"On Friday, OS Therapies, Inc.  entered into agreements for the commercial manufacture of OST-HER2.The company is currently organizing additional data about the recently completed treatment phase of its Phase 2b trial of OST-HER2 to prevent recurrence of lung metastatic osteosarcoma in preparation for a Type B or Type C FDA.Following the FDA meeting, the company anticipates submitting a Biologics Licensing Authorization  application to the FDA for accelerated or conditional approval consideration.In January, OS Therapiesrevealed data from a Phase 2b trial of OST-HER2 , a HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma, a rare, cancerous bone tumor that develops in bone-forming cells.Further, as of the most recent follow-up, the data show a strong trend in favor of OST-HER2-treated patients in overall survival  at the 1-year and 2-year interim time points of the ongoing 3-year overa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/small-cap-os-therapies-inks-185129548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","IP","OSTX","LU2463526074.USD","BK4139","BK4136","BK4585"],"gpt_icon":0},{"id":"2511991096","title":"BUZZ-OS Therapies rises after starting commercial production of cancer therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2511991096","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511991096?lang=en_us&edition=fundamental","pubTime":"2025-02-14 22:57","pubTimestamp":1739545028,"startTime":"0","endTime":"0","summary":"BUZZ-OS Therapies rises after starting commercial production of cancer therapy  ** Shares of drug developer OS Therapies OSTX.A rise 31.1% to $2.61 in morning trade  ** Co says it is starting commerci","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nL4N3P516S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2511225695","title":"OS Therapies Says It Signed Manufacturing Deal for Lead Candidate OST-HER2","url":"https://stock-news.laohu8.com/highlight/detail?id=2511225695","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511225695?lang=en_us&edition=fundamental","pubTime":"2025-02-14 22:29","pubTimestamp":1739543355,"startTime":"0","endTime":"0","summary":"OS Therapies  said Friday it has signed agreements to begin commercial manufacturing of its lead asset OST-HER2 as it prepares for a potential Biologics License Application submission to the US Food and Drug Administration.The company said it is compiling additional data from its recently completed phase 2b trial of OST-HER2 for lung metastatic osteosarcoma recurrence prevention.It plans to meet with the FDA for regulatory discussions before submitting a BLA for accelerated or conditional approval, OS Therapies added.Shares of the company were up more than 36% in recent Friday premarket activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4148","OST","OSTX","BK4139"],"gpt_icon":0},{"id":"2511249667","title":"BRIEF-OS Therapies Initiates Commercial-Ready Manufacturing Of OST-HER2 To Support Anticipated Biologics Licensing Authorization (BLA) Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2511249667","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511249667?lang=en_us&edition=fundamental","pubTime":"2025-02-14 21:03","pubTimestamp":1739538228,"startTime":"0","endTime":"0","summary":"BRIEF-OS Therapies Initiates Commercial-Ready Manufacturing Of OST-HER2 To Support Anticipated Biologics Licensing Authorization (BLA) FilingFeb 14 (Reuters) - OS Therapies Inc OSTX.A:OS THERAPIES INI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nFWN3P5190:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2511621506","title":"Os Therapies Initiates Commercial-Ready Manufacturing of Ost-Her2 to Support Anticipated Biologics Licensing Authorization (Bla) Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2511621506","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511621506?lang=en_us&edition=fundamental","pubTime":"2025-02-14 20:36","pubTimestamp":1739536584,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nFWN3P5190:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2508453448","title":"Os Therapies: Evaluating Strategic Options for Tunable Antibody Drug Conjugate Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2508453448","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508453448?lang=en_us&edition=fundamental","pubTime":"2025-02-04 20:33","pubTimestamp":1738672380,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250204:nTUA1FFWSZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2508145344","title":"Os Therapies Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2508145344","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508145344?lang=en_us&edition=fundamental","pubTime":"2025-02-04 20:33","pubTimestamp":1738672380,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250204:nTUA1FFWSZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2508990337","title":"OS Therapies files to sell 10.83M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2508990337","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508990337?lang=en_us&edition=fundamental","pubTime":"2025-02-01 05:25","pubTimestamp":1738358710,"startTime":"0","endTime":"0","summary":"16:24 EST OS Therapies (OSTX) files to sell 10.83M shares of common stock for holders Published first on TheFly – the ultimate source for real-time...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/os-therapies-files-to-sell-10-83m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/os-therapies-files-to-sell-10-83m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2507630349","title":"OS Therapies to Acquire Certain Ayala Pharmaceuticals Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2507630349","media":"MT Newswires Live","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507630349?lang=en_us&edition=fundamental","pubTime":"2025-01-29 23:48","pubTimestamp":1738165706,"startTime":"0","endTime":"0","summary":"OS Therapies  said Wednesday it agreed to acquire Ayala Pharmaceuticals' listeria monocytogenes-based immuno-oncology programs and related intellectual property assets.OS Therapies said it agreed to pay $500,000 in cash and issue $7.5 million worth of its common shares to Ayala under the deal, which is expected to close 60 days from the agreement's execution.The asset purchase deal includes a phase 2 lung cancer and phase 1 prostate cancer program, on top of gaining direct ownership of the underlying IP related to OS Therapies' OST-HER2 for osteosarcoma and other HER2-related indications, the company said.Shares of OS Therapies rose 9.3% in recent Wednesday trading.Price: 2.84, Change: +0.24, Percent Change: +9.27","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2507310506","title":"OS Therapies to acquire listeria programs from Ayala Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2507310506","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507310506?lang=en_us&edition=fundamental","pubTime":"2025-01-29 22:35","pubTimestamp":1738161325,"startTime":"0","endTime":"0","summary":"OS Therapies (OSTX) announced it has entered into an asset purchase agreement to acquire the listeria monocytogenes-based immuno-oncology programs ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/os-therapies-to-acquire-listeria-programs-from-ayala-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/os-therapies-to-acquire-listeria-programs-from-ayala-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2507639248","title":"Amex Halt  News Pending Lst 2.600000","url":"https://stock-news.laohu8.com/highlight/detail?id=2507639248","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507639248?lang=en_us&edition=fundamental","pubTime":"2025-01-29 22:30","pubTimestamp":1738161034,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250129:nAQN2JZS7G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2507639185","title":"Os Therapies Inc - to Request Bla for Ost-Her2 in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2507639185","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507639185?lang=en_us&edition=fundamental","pubTime":"2025-01-29 22:22","pubTimestamp":1738160520,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250129:nTUA4S6CSC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":105,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OSTX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OSTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OSTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1743652800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OSTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OSTX","date":"2025-06-13","current":-4.574874,"percent":0.80543,"low":-14.897496,"twenty":-11.315425,"median":-7.167274,"eighty":-4.590507,"high":-2.731469,"avg":-7.723832,"sd":3.415038,"marketCap":51699762},"quantilePoints":[{"date":"2024-06-14","current":-13.217965,"twenty":-13.216533,"median":-13.214385,"eighty":-13.212238,"marketCap":102988885},{"date":"2024-06-21","current":-10.574372,"twenty":-13.217965,"median":-13.214385,"eighty":-12.156232,"marketCap":82391108},{"date":"2024-06-28","current":-13.217965,"twenty":-13.217965,"median":-13.217965,"eighty":-13.210806,"marketCap":102988885},{"date":"2024-08-02","current":-6.458845,"twenty":-13.217965,"median":-13.217965,"eighty":-11.101659,"marketCap":50324634},{"date":"2024-08-09","current":-8.117559,"twenty":-13.217965,"median":-10.433676,"eighty":-8.215548,"marketCap":63248641},{"date":"2024-08-16","current":-10.993719,"twenty":-13.216533,"median":-10.29298,"eighty":-8.15204,"marketCap":70975778},{"date":"2024-08-23","current":-13.004275,"twenty":-13.182439,"median":-10.833368,"eighty":-8.309008,"marketCap":83955991},{"date":"2024-08-30","current":-11.710317,"twenty":-13.188909,"median":-11.710317,"eighty":-8.610078,"marketCap":75602161},{"date":"2024-09-06","current":-12.939577,"twenty":-13.217965,"median":-12.391225,"eighty":-8.620371,"marketCap":83538300},{"date":"2024-09-13","current":-11.32213,"twenty":-13.217965,"median":-12.261039,"eighty":-9.289415,"marketCap":73096012},{"date":"2024-09-20","current":-11.483875,"twenty":-13.217965,"median":-11.710317,"eighty":-10.29298,"marketCap":74140241},{"date":"2024-09-27","current":-9.575287,"twenty":-13.210806,"median":-11.435351,"eighty":-9.575287,"marketCap":61818342},{"date":"2024-10-04","current":-9.727327,"twenty":-13.101322,"median":-11.354479,"eighty":-9.316172,"marketCap":62799917},{"date":"2024-10-11","current":-9.931126,"twenty":-13.068973,"median":-11.192735,"eighty":-9.413543,"marketCap":64115645},{"date":"2024-10-18","current":-9.769381,"twenty":-13.068973,"median":-10.859351,"eighty":-9.542938,"marketCap":63071416},{"date":"2024-10-25","current":-9.413543,"twenty":-13.004275,"median":-10.610453,"eighty":-9.542938,"marketCap":60774113},{"date":"2024-10-31","current":-8.782738,"twenty":-12.952517,"median":-10.592413,"eighty":-9.394069,"marketCap":56701621},{"date":"2024-11-08","current":-9.085848,"twenty":-12.836061,"median":-10.29298,"eighty":-9.218608,"marketCap":58658505},{"date":"2024-11-15","current":-7.116768,"twenty":-12.603148,"median":-10.141393,"eighty":-8.950952,"marketCap":45946065},{"date":"2024-11-22","current":-5.272053,"twenty":-12.423258,"median":-9.769381,"eighty":-8.605027,"marketCap":38782655},{"date":"2024-11-29","current":-6.178419,"twenty":-12.235002,"median":-9.759676,"eighty":-8.507772,"marketCap":45450128},{"date":"2024-12-06","current":-5.370028,"twenty":-11.917351,"median":-9.716005,"eighty":-8.143742,"marketCap":39503383},{"date":"2024-12-13","current":-12.876517,"twenty":-11.917351,"median":-9.704683,"eighty":-7.804035,"marketCap":94723165},{"date":"2024-12-20","current":-11.288606,"twenty":-11.937313,"median":-9.73218,"eighty":-8.125896,"marketCap":83042057},{"date":"2024-12-27","current":-14.738704,"twenty":-12.001827,"median":-9.761941,"eighty":-8.139646,"marketCap":108421919},{"date":"2025-01-03","current":-12.068126,"twenty":-12.384347,"median":-9.850254,"eighty":-8.168424,"marketCap":88776420},{"date":"2025-01-10","current":-14.782011,"twenty":-12.810182,"median":-10.086184,"eighty":-8.234384,"marketCap":108740495},{"date":"2025-01-17","current":-11.8949,"twenty":-12.876517,"median":-10.189917,"eighty":-8.475423,"marketCap":87502117},{"date":"2025-01-24","current":-8.430366,"twenty":-12.823449,"median":-10.125219,"eighty":-8.466412,"marketCap":62016063},{"date":"2025-01-31","current":-5.629868,"twenty":-12.632281,"median":-9.850254,"eighty":-8.128675,"marketCap":41414837},{"date":"2025-02-07","current":-5.600996,"twenty":-12.558673,"median":-9.759676,"eighty":-7.471942,"marketCap":41202453},{"date":"2025-02-14","current":-5.745352,"twenty":-12.423258,"median":-9.716005,"eighty":-6.985183,"marketCap":42264372},{"date":"2025-02-21","current":-5.456641,"twenty":-12.370592,"median":-9.688508,"eighty":-6.36129,"marketCap":40140534},{"date":"2025-02-28","current":-4.734863,"twenty":-12.322192,"median":-9.575287,"eighty":-6.039722,"marketCap":34830939},{"date":"2025-03-07","current":-4.850347,"twenty":-12.19815,"median":-9.413543,"eighty":-5.818713,"marketCap":35680475},{"date":"2025-03-14","current":-4.619378,"twenty":-12.093217,"median":-9.316172,"eighty":-5.658739,"marketCap":33981404},{"date":"2025-03-21","current":-4.590507,"twenty":-12.033481,"median":-9.267973,"eighty":-5.589448,"marketCap":33769021},{"date":"2025-03-28","current":-4.677121,"twenty":-11.941094,"median":-9.085848,"eighty":-5.445093,"marketCap":34406172},{"date":"2025-04-04","current":-3.682014,"twenty":-11.842932,"median":-9.000397,"eighty":-5.346931,"marketCap":32707102},{"date":"2025-04-11","current":-2.731469,"twenty":-11.788323,"median":-8.747948,"eighty":-5.012916,"marketCap":24263468},{"date":"2025-04-17","current":-3.828934,"twenty":-11.749136,"median":-8.669517,"eighty":-4.901959,"marketCap":34012183},{"date":"2025-04-25","current":-3.926486,"twenty":-11.61974,"median":-8.601309,"eighty":-4.833024,"marketCap":34878735},{"date":"2025-05-02","current":-4.706906,"twenty":-11.475058,"median":-8.516979,"eighty":-4.792605,"marketCap":41811155},{"date":"2025-05-09","current":-4.804459,"twenty":-11.45771,"median":-8.491597,"eighty":-4.792605,"marketCap":42677707},{"date":"2025-05-16","current":-4.048427,"twenty":-11.438586,"median":-8.234384,"eighty":-4.718089,"marketCap":35961926},{"date":"2025-05-23","current":-2.933033,"twenty":-11.406237,"median":-8.124506,"eighty":-4.677121,"marketCap":33145630},{"date":"2025-05-30","current":-3.928425,"twenty":-11.380358,"median":-7.63641,"eighty":-4.64825,"marketCap":44394361},{"date":"2025-06-06","current":-4.052742,"twenty":-11.348009,"median":-7.333748,"eighty":-4.596281,"marketCap":45799246},{"date":"2025-06-13","current":-4.574874,"twenty":-11.315425,"median":-7.167274,"eighty":-4.590507,"marketCap":51699762}],"updateTime":1750065794376}}}